Literature DB >> 21239992

Cancer in HIV-infected persons from the Caribbean, Central and South America.

Valeria I Fink1, Bryan E Shepherd, Carina Cesar, Alejandro Krolewiecki, Firas Wehbe, Claudia P Cortés, Brenda Crabtree-Ramírez, Denis Padgett, Maryam Shafaee, Mauro Schechter, Eduardo Gotuzzo, Melanie Bacon, Catherine McGowan, Pedro Cahn, Daniel Masys.   

Abstract

BACKGROUND: HIV-infected individuals have heightened cancer risk. With the advent of highly active antiretroviral therapy (HAART), the frequency of some AIDS-defining cancers (ADC) has decreased although certain non-AIDS-defining cancers (NADC) are becoming more frequent. Cancers among HIV-infected individuals in Latin American and the Caribbean have not yet been carefully studied.
METHODS: Cancer cases among the Caribbean, Central and South American network for HIV Research (CCASAnet) cohort were identified reviewing clinical records and pre-existing databases.
RESULTS: There were 406 cancers reported: 331 ADC (224 Kaposi sarcomas and 98 non Hodgkin lymphomas). Most frequent NADC (n = 75) were Hodgkin lymphoma and skin cancers. Seventy-three percent of NADC and 45% of ADC were diagnosed >1 year after HIV diagnosis. Fifty-six percent of ADC occurred before HAART start. Median time from HAART start until cancer diagnosis was 2.5 years for NADC and 0.5 years for ADC (P = <0.001). Within 3372 HAART starters, 158 were diagnosed with 165 cancers (82.4% ADC); 85 cases were previous to or concomitant with HAART initiation. Incidence of cancer after HAART initiation in 8080 person-years of follow-up was 7.2 per 1000 person-years (95% confidence interval = 5.5 to 9.3) for ADC and 2.7 (95% confidence interval = 1.8 to 4.1) for NADC; incidence was higher in the first 2 months, particularly for ADC (47.6). A pre-HAART ADC was a predictor of mortality after adjusting for age, sex, and CD4 at HAART initiation.
CONCLUSIONS: ADC were the most frequent cancers in this region and were often diagnosed close to HIV diagnosis and HAART start. Incidence of cancer was highest around HAART initiation.

Entities:  

Mesh:

Year:  2011        PMID: 21239992      PMCID: PMC3293455          DOI: 10.1097/QAI.0b013e31820bb1c3

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  33 in total

1.  Association of cancer with AIDS-related immunosuppression in adults.

Authors:  M Frisch; R J Biggar; E A Engels; J J Goedert
Journal:  JAMA       Date:  2001-04-04       Impact factor: 56.272

2.  HIV-related malignancies pre- and post-highly active antiretroviral therapy: experiences in an inner city tertiary referral centre.

Authors:  B Kiely; J O'Flaherty; S Surah; J Kieran; D O'Donnell; C Bergin; F Mulcahy
Journal:  Int J STD AIDS       Date:  2010-05       Impact factor: 1.359

3.  The impact of Kaposi sarcoma and non-Hodgkin lymphoma on mortality of people with AIDS in the highly active antiretroviral therapies era.

Authors:  Diego Serraino; Angela De Paoli; Antonella Zucchetto; Simona Pennazza; Silvia Bruzzone; Michele Spina; Paolo De Paoli; Giovanni Rezza; Luigino Dal Maso; Barbara Suligoi
Journal:  Cancer Epidemiol       Date:  2010-04-22       Impact factor: 2.984

Review 4.  Malignancies in women with HIV infection.

Authors:  Amrita Krishnan; Alexandra M Levine
Journal:  Womens Health (Lond)       Date:  2008-07

5.  Rates and reasons for early change of first HAART in HIV-1-infected patients in 7 sites throughout the Caribbean and Latin America.

Authors:  Carina Cesar; Bryan E Shepherd; Alejandro J Krolewiecki; Valeria I Fink; Mauro Schechter; Suely H Tuboi; Marcelo Wolff; Jean W Pape; Paul Leger; Denis Padgett; Juan Sierra Madero; Eduardo Gotuzzo; Omar Sued; Catherine C McGowan; Daniel R Masys; Pedro E Cahn
Journal:  PLoS One       Date:  2010-06-01       Impact factor: 3.240

6.  Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy: not all AIDS-defining conditions are created equal.

Authors:  Amanda Mocroft; Jonathan A C Sterne; Matthias Egger; Margaret May; Sophie Grabar; Hansjakob Furrer; Caroline Sabin; Gerd Fatkenheuer; Amy Justice; Peter Reiss; Antonella d'Arminio Monforte; John Gill; Robert Hogg; Fabrice Bonnet; Mari Kitahata; Schlomo Staszewski; Jordi Casabona; Ross Harris; Michael Saag
Journal:  Clin Infect Dis       Date:  2009-04-15       Impact factor: 9.079

Review 7.  Cancer: the effects of HIV and antiretroviral therapy, and implications for early antiretroviral therapy initiation.

Authors:  Andrew E Grulich
Journal:  Curr Opin HIV AIDS       Date:  2009-05       Impact factor: 4.283

8.  Mortality during the first year of potent antiretroviral therapy in HIV-1-infected patients in 7 sites throughout Latin America and the Caribbean.

Authors:  Suely H Tuboi; Mauro Schechter; Catherine C McGowan; Carina Cesar; Alejandro Krolewiecki; Pedro Cahn; Marcelo Wolff; Jean W Pape; Denis Padgett; Juan Sierra Madero; Eduardo Gotuzzo; Daniel R Masys; Bryan E Shepherd
Journal:  J Acquir Immune Defic Syndr       Date:  2009-08-15       Impact factor: 3.731

9.  Highly active antiretroviral therapy and the incidence of non-AIDS-defining cancers in people with HIV infection.

Authors:  Thomas Powles; David Robinson; Justin Stebbing; Jonathan Shamash; Mark Nelson; Brian Gazzard; Sundhiya Mandelia; Henrik Møller; Mark Bower
Journal:  J Clin Oncol       Date:  2008-12-29       Impact factor: 44.544

Review 10.  Human papillomavirus and HIV coinfection and the risk of neoplasias of the lower genital tract: a review of recent developments.

Authors:  Alex Ferenczy; François Coutlée; Eduardo Franco; Catherine Hankins
Journal:  CMAJ       Date:  2003-09-02       Impact factor: 8.262

View more
  9 in total

1.  Incidence rate of Kaposi sarcoma in HIV-infected patients on antiretroviral therapy in Southern Africa: a prospective multicohort study.

Authors:  Eliane Rohner; Fabio Valeri; Mhairi Maskew; Hans Prozesky; Helena Rabie; Daniela Garone; Diana Dickinson; Cleophas Chimbetete; Priscilla Lumano-Mulenga; Izukanji Sikazwe; Natascha Wyss; Kerri M Clough-Gorr; Matthias Egger; Benjamin H Chi; Julia Bohlius
Journal:  J Acquir Immune Defic Syndr       Date:  2014-12-15       Impact factor: 3.731

2.  The effect of HIV and HPV coinfection on cervical COX-2 expression and systemic prostaglandin E2 levels.

Authors:  Daniel W Fitzgerald; Karl Bezak; Oksana Ocheretina; Cynthia Riviere; Thomas C Wright; Ginger L Milne; Xi Kathy Zhou; Baoheng Du; Kotha Subbaramaiah; Erin Byrt; Matthew L Goodwin; Arash Rafii; Andrew J Dannenberg
Journal:  Cancer Prev Res (Phila)       Date:  2011-12-01

3.  Non-Hodgkin lymphoma risk in adults living with HIV across five continents.

Authors: 
Journal:  AIDS       Date:  2018-11-28       Impact factor: 4.632

4.  HIV and cancer: a comparative retrospective study of Brazilian and U.S. clinical cohorts.

Authors:  Jessica L Castilho; Paula M Luz; Bryan E Shepherd; Megan Turner; Sayonara R Ribeiro; Sally S Bebawy; Juliana S Netto; Catherine C McGowan; Valdiléa G Veloso; Eric A Engels; Timothy R Sterling; Beatriz Grinsztejn
Journal:  Infect Agent Cancer       Date:  2015-02-02       Impact factor: 2.965

5.  Association between Highly Active Antiretroviral Therapy and Type of Infectious Respiratory Disease and All-Cause In-Hospital Mortality in Patients with HIV/AIDS: A Case Series.

Authors:  Renata Báez-Saldaña; Adriana Villafuerte-García; Pablo Cruz-Hervert; Guadalupe Delgado-Sánchez; Leticia Ferreyra-Reyes; Elizabeth Ferreira-Guerrero; Norma Mongua-Rodríguez; Rogelio Montero-Campos; Ada Melchor-Romero; Lourdes García-García
Journal:  PLoS One       Date:  2015-09-17       Impact factor: 3.240

6.  Frequency of non-communicable diseases in people 50 years of age and older receiving HIV care in Latin America.

Authors:  Pablo F Belaunzaran-Zamudio; Yanink Caro-Vega; Mark J Giganti; Jessica L Castilho; Brenda E Crabtree-Ramirez; Bryan E Shepherd; Fernando Mejía; Carina Cesar; Rodrigo C Moreira; Marcelo Wolff; Jean W Pape; Denis Padgett; Catherine C McGowan; Juan G Sierra-Madero
Journal:  PLoS One       Date:  2020-06-17       Impact factor: 3.240

7.  Survival after cancer diagnosis in a cohort of HIV-positive individuals in Latin America.

Authors:  Valeria I Fink; Cathy A Jenkins; Jessica L Castilho; Anna K Person; Bryan E Shepherd; Beatriz Grinsztejn; Juliana Netto; Brenda Crabtree-Ramirez; Claudia P Cortés; Denis Padgett; Karu Jayathilake; Catherine McGowan; Pedro Cahn
Journal:  Infect Agent Cancer       Date:  2018-05-08       Impact factor: 2.965

8.  Non-AIDS defining cancer (NADC) among HIV-infected patients at an oncology tertiary-care center in Mexico.

Authors:  P Cornejo-Juárez; D Cavildo-Jerónimo; P Volkow-Fernández
Journal:  AIDS Res Ther       Date:  2018-10-27       Impact factor: 2.250

9.  Antiretroviral therapy and Kaposi's sarcoma trends and outcomes among adults with HIV in Latin America.

Authors:  Jessica L Castilho; Ahra Kim; Cathy A Jenkins; Beatriz Grinsztejn; Eduardo Gotuzzo; Valeria Fink; Denis Padgett; Pablo F Belaunzaran-Zamudio; Brenda Crabtree-Ramírez; Maria Mercedes Escuder; Rosa Alencar Souza; Simone B Tenore; Sidnei R Pimentel; Maria Letícia Rodrigues Ikeda; Paulo R de Alencastro; Unai Tupinanbas; Carlos Brites; Estela Luz; Juliana Netto; Claudia P Cortes; Alexandre Grangeiro; Bryan E Shepherd; Catherine C McGowan
Journal:  J Int AIDS Soc       Date:  2021-01       Impact factor: 6.707

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.